Hilleman Labs Makeover Rides On New Technology For Heat-stable Rotavirus Vaccines
This article was originally published in PharmAsia News
Executive Summary
The vaccines research JV between Merck and Wellcome Trust has undergone major changes in its operations. The new plan is dramatically different from the one envisioned at the launch of the JV and narrows down on fewer disease areas with a predominant presence in enteric illnesses.
You may also be interested in...
Merck JV Ties Up With MEND To Focus On First Heat-stable Rotavirus Vaccine For Developing Markets
MUMBAI - Hilleman Laboratories - the nonprofit joint venture between Merck & Co. and Wellcome Trust to develop affordable vaccines for low-income countries - has set its sights on developing a heat-stable form of rotavirus vaccine as its first project
With More Vaccines For Low-Income Countries In Mind, Merck Signs JV With Wellcome Trust; India To Be Research And Manufacturing Hub
MUMBAI - New opportunities like preventive vaccines for developing countries are throwing up newer alliances between disparate stakeholders. In one such deal, New Jersey-headquartered Merck has formed a first-of-its-kind equal stake collaboration with Wellcome Trust of the United Kingdom to work on research and development of vaccines that can prevent diseases mainly in low-income countries
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.